New Perspectives for the Treatment of Alzheimer's Disease and Drug-Related Secretions for Blood Pressure

In the United States, a clinical trial showed that people on intensive antihypertensive treatment were at a lower risk of developing cognitive impairment, the first stage of Alzheimer's disease.

However, the history of research on this disease has been disappointing, leading to a cautious approach to this study, published in the Journal of the American Medical Association (Gama), entitled "Sprint Mind".

However, the large number of study participants and the high statistical quality of one of its findings will make it an important tool for finding the desired treatment for this disease, which is still difficult today. .

This experience is the first to find a way to prevent memory problems or to concentrate in the elderly.

"This is the first experience that shows an effective strategy against the prevention of age-related cognitive impairment," writes Christine Yaff, a neuroscientist specializing in neurodegenerative diseases at the University of California in San Francisco.

The clinical trial involved more than 9,000 adults over the age of 50 suffering from high blood pressure.

Half of them received treatment aimed at lowering the systolic pressure level (the first between the two numbers used to measure blood pressure) to less than 140 milligrams of mercury, and set themselves a more ambitious goal for the second half of reducing levels below 120 millimeters of mercury.

After a follow-up period of 5 years on average, the doctors found no difference between the two groups in terms of measuring the "possible dementia".

On the other hand, the intensive group had lower levels of "mild cognitive impairment" than those in the other group.

According to the Alzheimer's Association, the slight decline in cognitive abilities includes apparent difficulties in choosing the right words or names, as well as difficulties in remembering people's names soon after meeting them or for forgetting information far away. to be read.

All people with Alzheimer's disease have gone through this stage, but this condition does not affect anyone with mild cognitive abilities.

The study also confirms the idea that "what is good for the heart is also beneficial for the brain," said Scientific Director of the Alzheimer's Association, Maria Carrio.

However, this study does not conclusively conclude that the treatment of high blood pressure can prevent Alzheimer's disease.

Maria Carrillo announced that the badociation would fund an extension of the study for a period of two years, in order to badess the situation of patients over a longer period with a more advanced age.